© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September 15th 2020, 5:30pm
Sickle cell disease is a costly disease for patients, but when those patients suffer from end-organ damage, the costs jump significantly.
September 11th 2020, 11:30am
A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.
September 9th 2020, 4:00pm
New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.
September 3rd 2020, 5:00pm
A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.
August 31st 2020, 7:30pm
A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.
August 26th 2020, 3:30pm
A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.
August 17th 2020, 9:45am
Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.
August 16th 2020, 1:00pm
Investigators have made tremendous strides improving patient care in multiple myeloma (MM), but the authors of a new review article say much more work is needed.
August 15th 2020, 9:39pm
Clinical updates for August 2020 featured in Evidence-Based Oncology.
August 14th 2020, 4:00am
Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma.